脑调序疗法应用于首发精神分裂症患者的临床研究

Clinical Studies on the Brain Modulating-order Therapy Applying to the First Episode Patients with Schizophrenia

目的探讨以脑调序疗法治疗首发精神分裂症的适用范围、疗效及安全性。方法将符合诊断标准的能够配合治疗及评估的首发精神分裂症患者109例,随机分成2组,分别给予维思通和脑调序仪治疗8周,采用PANSS及TESS量表评定其疗效和副反应,组间比较采用t检验及χ2检验,两组患者均给予半年以上的院外随访。结果维思通组与脑调序组总体疗效无明显差异(P>0.05),但对于反应缺乏组症状群,脑调序组治疗效果不如维思通组(P<0.05)。阴性量表分减分率脑调序组稍低于维思通组,但无统计学差异(P>0.05)。TESS评定脑调序组副反应比维思通组小(P<0.01)。院外随访脑调序组患者回归社会率高(52.9%),复发率低(7.8%)。结论脑调序法治疗首发精神分裂症适用范围较广,疗效好,安全性高,复发率低,临床值得推广。

Objective To study the applicable range, effects and safety of the brain modulating-order therapy to the first episode schizophrenia. Methods 109 patients with schizophrenia who met the diagnosis criteria and could cooperate in therapy and evaluation were divided into two groups randomly, which accepted the brain modulating-order therapy and Risperdal 8 weeks respectively. We evaluated theeffects and side effects by PANSS and TESS scales. Moreover, we followed up the discharged patients for at least six months. Results The difference of general effects between the brain modulating-order group and the Risperdal group is of no significance statistically （P〉0. 05）, however, for the symptoms of response absence , the effects of brain modulating-order group are not as good as those of the Risperdal group（P〈0. 05）. Meanwhile, the reduction rate of negative scale scores of the former is somewhat lower than that of the latter, but the difference was of no significance statistically. The TESS evaluation showed that the side effect of the former is lower than that of the latter（P〈0.01）. Finally, the patients who accepted the brain modulating-order therapy have a better rate of return to society and a lower rate of recurrence. Conclusion For the first episode patients with schizophrenia, the brain modulating-order therapy has a comparatively wide applicable range, nice effects, high safety and low rate of recurrence, so it deserves clinical popularization.